Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Completed 11Terminated 10Active not recruiting 8Recruiting 5Withdrawn 2

Sponsor Class

OTHER 3NIH 1NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 5CNS 1

Conditions

Carcinoma, Renal Cell 6Melanoma 5Clear-cell metastatic renal cell carcinoma 4Mycosis Fungoides 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sjogren's Syndrome 1Scleroderma, Systemic 1Psoriasis 1Prostatic Neoplasms 1Penile Neoplasms 1Nasopharyngeal Carcinoma 1Myelodysplastic Syndromes 1Multiple Sclerosis 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, B-Cell 1Lupus Erythematosus, Systemic 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Inflammatory Bowel Diseases 1Immunoblastic Lymphadenopathy 1Hematologic Neoplasms 1

Interventions

pembrolizumab 54Nivolumab 51Ipilimumab 29Cyclophosphamide 16binimetinib 10Specimen Handling 10Magnetic Resonance Spectroscopy 10fludarabine 9Radiosurgery 9relatlimab 8encorafenib 8Opdualag 8Interleukin-2 8Biopsy 8aldesleukin 7Blood Specimen Collection 7atezolizumab 6Immunotherapy 6cemiplimab 5CTLA-4 Antigen 5Bevacizumab 5trametinib 4dabrafenib 4Temozolomide 4Paclitaxel 4Immune Checkpoint Inhibitors 4spartalizumab 3fludarabine phosphate 3Surgical Procedures, Operative 3Metformin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Melanoma × CTLA-4 Antigen × Clear all
NCT05896839 2026-05-13

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

National Cancer Institute (NCI)

Phase 1/2 Recruiting
16 enrolled
Dermatologic

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

NCT04697576 2026-03-10

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

Ohio State University Comprehensive Cancer Center

Phase 1 Recruiting
36 enrolled
Dermatologic

Melanoma

NCT05428007 2026-01-05

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

NYU Langone Health

Phase 2 Recruiting
105 enrolled
Dermatologic

Melanoma

NCT07155317 2025-11-12

Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial

Emory University

Phase 2 Recruiting
99 enrolled
Dermatologic

Melanoma

NCT04511013 2025-09-11

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

SWOG Cancer Research Network

Phase 2 Recruiting
112 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡